Skip to content

Study · Not a test of the peptide alone · 2025

6 results

Silica-Assisted Solid-Phase Peptide Synthesis (SiPPS).

Nkwanyana N, Kumar A, Chakraborty A, Potvin S, Thibaut-Koumba G, Nardone B, Beland F, Sharma A, de la Torre BG, Albericio F

Journal of peptide science : an official publication of the European Peptide Society1 Sept 2025Cited by 3 (Europe PMC)

PMID40817749 (opens in a new tab)PMCIDPMC12357219 (opens in a new tab)DOI10.1002/psc.70052 (opens in a new tab)PepBankPUB-40817749
Read at sourcePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study6

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone6

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

  1. 01LabNot a test of Melanotan I (afamelanotide) aloneOther designOther

    Silica-assisted solid-phase synthesis, demonstrated for afamelanotide among other peptides, allowed a 50% reduction in solvent consumption.

    In plain wordsIn lab synthesis, a silica resin cut solvent use by 50% for afamelanotide and other peptides.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    DecreaseSolvent consumption in synthesis
    Study

    n: not reported in source

    Outcome group
    Synthesis and manufacturing · Pharmacology

    Source sentences

    Summary
    The use of this non-swelling resin allows a 50% reduction in the consumption of solvents.
    1 context sentence
    Summary · context
    The strategy was well demonstrated for the synthesis of H-YSSFL-NH2, linear oxytocin, angiotensin II, and afamelanotide using a silica-based support (Fmoc-Rink amide SiliaBond manufactured from SiliCycle Inc.).

    In this study, Melanotan I (afamelanotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Melanotan I (afamelanotide).

  2. 02LabNot a test of Melanotan I (afamelanotide) aloneOther designOther

    Peptides made by silica-assisted solid-phase synthesis, including afamelanotide, had more than acceptable purity.

    In plain wordsIn lab synthesis, the peptides, afamelanotide included, had more than acceptable purity.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    Not applicablePurity of synthesized peptide
    Study

    n: not reported in source

    Outcome group
    Synthesis and manufacturing · Pharmacology

    Source sentences

    Summary
    The peptides were found to have more than acceptable purity, although there was a loss in overall yields.
    1 context sentence
    Summary · context
    The strategy was well demonstrated for the synthesis of H-YSSFL-NH2, linear oxytocin, angiotensin II, and afamelanotide using a silica-based support (Fmoc-Rink amide SiliaBond manufactured from SiliCycle Inc.).

    In this study, Melanotan I (afamelanotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Melanotan I (afamelanotide).

  3. 03LabNot a test of Melanotan I (afamelanotide) aloneOther designOther

    Peptides made by silica-assisted solid-phase synthesis, including afamelanotide, had a loss in overall yields.

    In plain wordsIn lab synthesis, the overall yield of the peptides, afamelanotide included, was lower.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    DecreaseOverall yield of synthesized peptide
    Study

    n: not reported in source

    Outcome group
    Synthesis and manufacturing · Pharmacology

    Source sentences

    Summary
    The peptides were found to have more than acceptable purity, although there was a loss in overall yields.
    1 context sentence
    Summary · context
    The strategy was well demonstrated for the synthesis of H-YSSFL-NH2, linear oxytocin, angiotensin II, and afamelanotide using a silica-based support (Fmoc-Rink amide SiliaBond manufactured from SiliCycle Inc.).

    In this study, Melanotan I (afamelanotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Melanotan I (afamelanotide).

  4. 04LabNot a test of Oxytocin aloneOther designOther

    Silica-assisted solid-phase synthesis, demonstrated for linear oxytocin among other peptides, allowed a 50% reduction in solvent consumption.

    In plain wordsIn lab synthesis, a silica resin cut solvent use by 50% for linear oxytocin and other peptides.

    Peptide
    Oxytocin
    Outcome
    DecreaseSolvent consumption in synthesis
    Study

    n: not reported in source

    Outcome group
    Synthesis and manufacturing · Pharmacology

    Source sentences

    Summary
    The use of this non-swelling resin allows a 50% reduction in the consumption of solvents.
    1 context sentence
    Summary · context
    The strategy was well demonstrated for the synthesis of H-YSSFL-NH2, linear oxytocin, angiotensin II, and afamelanotide using a silica-based support (Fmoc-Rink amide SiliaBond manufactured from SiliCycle Inc.).

    In this study, Oxytocin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Oxytocin.

  5. 05LabNot a test of Oxytocin aloneOther designOther

    Peptides made by silica-assisted solid-phase synthesis, including linear oxytocin, had more than acceptable purity.

    In plain wordsIn lab synthesis, the peptides, linear oxytocin included, had more than acceptable purity.

    Peptide
    Oxytocin
    Outcome
    Not applicablePurity of synthesized peptide
    Study

    n: not reported in source

    Outcome group
    Synthesis and manufacturing · Pharmacology

    Source sentences

    Summary
    The peptides were found to have more than acceptable purity, although there was a loss in overall yields.
    1 context sentence
    Summary · context
    The strategy was well demonstrated for the synthesis of H-YSSFL-NH2, linear oxytocin, angiotensin II, and afamelanotide using a silica-based support (Fmoc-Rink amide SiliaBond manufactured from SiliCycle Inc.).

    In this study, Oxytocin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Oxytocin.

  6. 06LabNot a test of Oxytocin aloneOther designOther

    Peptides made by silica-assisted solid-phase synthesis, including linear oxytocin, had a loss in overall yields.

    In plain wordsIn lab synthesis, the overall yield of the peptides, linear oxytocin included, was lower.

    Peptide
    Oxytocin
    Outcome
    DecreaseOverall yield of synthesized peptide
    Study

    n: not reported in source

    Outcome group
    Synthesis and manufacturing · Pharmacology

    Source sentences

    Summary
    The peptides were found to have more than acceptable purity, although there was a loss in overall yields.
    1 context sentence
    Summary · context
    The strategy was well demonstrated for the synthesis of H-YSSFL-NH2, linear oxytocin, angiotensin II, and afamelanotide using a silica-based support (Fmoc-Rink amide SiliaBond manufactured from SiliCycle Inc.).

    In this study, Oxytocin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Oxytocin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 2

    13 Oct 2026, 16:31 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 02:48 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.